drugset / Trial / NCT03609424
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
NaSingle-groupOpen-labelTreatment
Summary
Assuming that PDR001, an anti-PD-1 antibody, with imatinib might be effective in advanced GIST after failure of standard TKI therapies including imatinib, sunitinib, and regorafenib. In this phase I/II study of PDR001 plus imatinib, it is aimed to evaluate the safety and efficacy of this regimen as 4th line of treatment in advanced GIST.
Timeline
- Start
- 2019-02-14
- Primary completion
- 2021-11-11
- Completion
- 2021-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 200 mg | Oral |
| Subject | Imatinib | Small molecule | 300 mg | Oral |
| Subject | Imatinib | Small molecule | 400 mg | Oral |
| Subject | Spartalizumab | Monoclonal antibody | 400 mg | Intravenous |